Atea Pharmaceuticals (AVIR) Operating Leases (2022 - 2025)

Atea Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $213000.0 for Q3 2025.

• On a quarterly basis, Operating Leases fell 79.62% year-over-year to $213000.0 in Q3 2025; TTM through Sep 2025 was $213000.0, a 79.62% decrease from a year earlier, with the FY2024 full-year figure at $842000.0, down 48.72% from the prior year.
• Operating Leases eased to $213000.0 in Q3 2025 per AVIR's latest filing, from $425000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $2.8 million in Q2 2022 and bottomed at $213000.0 in Q3 2025.
• The 4-year median for Operating Leases is $1.6 million (2023), against an average of $1.6 million.
• Across the five-year window, Operating Leases declined 19.83% in 2023 and tumbled 79.62% in 2025, its largest moves.
• Year by year, Operating Leases stood at $2.4 million in 2022, then sank by 31.67% to $1.6 million in 2023, then slumped by 48.72% to $842000.0 in 2024, then sank by 74.7% to $213000.0 in 2025.
• Per Business Quant, the three latest AVIR Operating Leases figures stand at $213000.0 (Q3 2025), $425000.0 (Q2 2025), and $634000.0 (Q1 2025).